^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

    Excerpt:
    ...- Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with vemurafenib -...
    Trial ID:
    MELANIS
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Proc Natl Acad Sci U S A
    Title:

    Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma

    Published date:
    08/15/2022
    Excerpt:
    Combinatorial therapy involving bromosporine and cobimetinib (bromo/cobi) showed synergistic anti-tumor effects in multiple BRAFi-resistant PDX models. The bromo/cobi combination was superior in vivo to standard BRAFi/MEKi therapy in the treatment-naive BRAF-mutant setting and to MEKi alone in the setting of immunotherapy-resistant NRAS- and NF1-mutant melanoma.
    DOI:
    10.1073/pnas.2206824119